Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06397781 · ClinicalTrials.gov registry record · Phase 4
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
A Phase 4 study, sponsored by Boston Children's Hospital.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT06397781 is a Phase 4 study that has not yet begun recruiting, run by Boston Children's Hospital. The registered enrollment target is 100 participants.
The verdict
NCT06397781, a Phase 4 study, has not yet begun recruiting, sponsored by Boston Children's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.
Interventions
- DRUG Skin Cleanser Combination No.1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2031-01-01 |
| Est. Completion | 2039-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06397781
The ClinicalTrials.gov registry entry for NCT06397781 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Skin Cleanser Combination No.1 is the first listed.
NCT06397781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06397781 about?
NCT06397781 is a clinical study titled "Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients". Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.
What is the current status of trial NCT06397781?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2031-01-01. Estimated completion is 2039-12.
What interventions are being tested in trial NCT06397781?
The interventions under investigation include: Skin Cleanser Combination No.1 (DRUG).
Who is sponsoring clinical trial NCT06397781?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.